EUVIMEDDescoperă EUVIMED
KohortenstudieOpen access · CC BY 4.0

Impact of kimura-takemoto atrophy classification on first-line H. pylori eradication: a retrospective cohort study

Dongchu Wang, Xiangwu Ding, Aixiang Wang

Frontiers in Medicine · 2026-06-19 · 13

DOI: 10.3389/fmed.2026.1864653 ↗

At a glance

Kohortenstudie in Frontiers in Medicine, published online on 2026-06-19. Written by Dongchu Wang and 2 co-authors. Institution: Department of Gastroenterology, Wuhan Fourth Hospital, Wuhan, China. 47 references. The full text is freely available (open access, CC BY 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Objective

We sought to determine whether the endoscopic grade of gastric atrophy (according to Kimura-Takemoto) affects the likelihood of successful first-line H. pylori eradication.

Methods

We conducted a retrospective analysis of consecutive patients hospitalized at Wuhan Fourth Hospital between November 2021 and November 2025. Eligible individuals had a positive urea breath test confirming H. pylori infection, were diagnosed with chronic atrophic gastritis via gastroscopy, received a bismuth-containing quadruple regimen as first-line therapy, and returned for a follow-up breath test at least 4 weeks post-treatment. Prior to therapy (within 28 days), each patient underwent high-definition white-light gastroscopy. Two independent endoscopists, unaware of patient allocation, retrospectively reviewed all images to grade atrophy using the Kimura-Takemoto system. Patients were assigned to either the closed-type (C-type) or open-type (O-type) atrophy group. The primary endpoint was eradication failure, defined as a positive follow-up breath test. Logistic regression (univariate and multivariate) was used to identify factors independently linked to treatment failure.

Results

A total of 154 patients completed follow-up and were included. The overall eradication rate was 76.6% (118/154). In the open-type atrophy group ( n = 26), the eradication rate was only 42.3% (11/26), significantly lower than the 83.6% (107/128) observed in the closed-type group ( P < 0.001). After adjusting for confounders such as body weight and age, multivariate analysis revealed that endoscopic open-type atrophy was independently associated with eradication failure (OR = 8.287, 95% CI: 3.150–21.804, P < 0.001).

Conclusion

The extent of endoscopic gastric mucosal atrophy independently predicts a lower efficacy of first-line H. pylori eradication. For patients with Kimura-Takemoto open-type atrophy, clarithromycin-containing quadruple regimens should be used cautiously. Alternative clarithromycin-free regimens (e.g., tetracycline-, metronidazole-, or levofloxacin-based therapies, or high-dose amoxicillin with PPI/vonoprazan) or susceptibility-guided individualized therapy are recommended in clinical practice.

Subjects

Author keywords

clarithromycineradication therapygastric atrophyhelicobacter pylorikimura-takemoto classification

Authors and institutions

  • Department of Gastroenterology, Wuhan Fourth Hospital, Wuhan, China.

Cite

APA

Wang, D., Ding, X., & Wang, A. (2026). Impact of kimura-takemoto atrophy classification on first-line H. pylori eradication: a retrospective cohort study. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1864653

Vancouver

Wang D, Ding X, Wang A. Impact of kimura-takemoto atrophy classification on first-line H. pylori eradication: a retrospective cohort study. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1864653

BibTeX
@article{Wang2026,
  author = {Wang, Dongchu and Ding, Xiangwu and Wang, Aixiang},
  title = {Impact of kimura-takemoto atrophy classification on first-line H. pylori eradication: a retrospective cohort study},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1864653}
}
Start for free →